CD274 and non-small cell lung carcinoma: 74.0% (154/208) of mUC, 70.4% (57/81) of NSCLC, and 62.3% (48/77) of RCC tumors were PD-L1+ (Supplementary Fig. 1c and Supplementary Data 1).